FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890773244> ?p ?o ?g. }

• W2890773244 endingPage "320" @default.
• W2890773244 startingPage "320" @default.
• W2890773244 abstract "Introduction: Pharmacovigilance may detect safety issues after marketing of medications, and this can result in regulatory action such as direct healthcare professional communications (DHPC). DHPC can be effective in changing prescribing behaviour, however the extent to which prescribers vary in their response to DHPC is unknown. This study aims to explore changes in prescribing and prescribing variation among general practitioner (GP) practices following a DHPC on the safety of mirabegron, a medication to treat overactive bladder (OAB). Methods: This is an interrupted time series study of English GP practices from 2014–2017. National Health Service (NHS) Digital provided monthly statistics on aggregate practice-level prescribing and practice characteristics (practice staff and registered patient profiles, Quality and Outcomes Framework indicators, and deprivation of the practice area). The primary outcome was monthly mirabegron prescriptions as a percentage of all OAB drug prescriptions and we assessed the change following a DHPC issued by the European Medicines Agency in September 2015. The DHPC stated mirabegron use was contraindicated with severe uncontrolled hypertension and cautioned with hypertension. Variation between practices in mirabegron prescribing before and after the DHPC was assessed using the systematic component of variation (SCV). Multilevel segmented regression with random effects quantified the change in level and trend of prescribing after the DHPC. Practice characteristics were assessed for their association with a reduction in prescribing following the DHPC. Results: This study included 7408 practices. During September 2015, 88.9% of practices prescribed mirabegron and mirabegron comprised a mean of 8.2% (SD 6.8) of OAB prescriptions. Variation between practices was classified as very high and the median SCV did not change significantly (p = 0.11) in the six months after the September 2015 DHPC (12.4) compared to before (11.6). Before the DHPC, the share of mirabegron over all OAB drug prescriptions increased by 0.294 (95% confidence interval (CI), 0.287, 0.301) percentage points per month. There was no significant change in the month immediately after the DHPC (−0.023, 95% CI −0.105 to 0.058), however there was a significant reduction in trend (−0.036, 95% CI −0.049 to −0.023). Higher numbers of registered patients, patients aged ≥65 years, and practice area deprivation were associated with having a significant decrease in level and slope of mirabegron prescribing post-DHPC. Conclusion: Variation in mirabegron prescribing was high over the study period and did not change substantively following the DHPC. There was no immediate prescribing change post-DHPC, although the monthly growth did slow. Knowledge of the degree of variation in and determinants of response to safety communications may allow those that do not change prescribing habits to be provided with additional support." @default.
• W2890773244 created "2018-09-27" @default.
• W2890773244 creator A5009156847 @default.
• W2890773244 creator A5018068367 @default.
• W2890773244 creator A5023756839 @default.
• W2890773244 creator A5061507341 @default.
• W2890773244 date "2018-10-03" @default.
• W2890773244 modified "2023-09-23" @default.
• W2890773244 title "Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron" @default.
• W2890773244 cites W1578634963 @default.
• W2890773244 cites W1894577352 @default.
• W2890773244 cites W1971620454 @default.
• W2890773244 cites W1983095703 @default.
• W2890773244 cites W1986471490 @default.
• W2890773244 cites W1988039876 @default.
• W2890773244 cites W2003004850 @default.
• W2890773244 cites W2022245473 @default.
• W2890773244 cites W2050857666 @default.
• W2890773244 cites W2051463821 @default.
• W2890773244 cites W2067203891 @default.
• W2890773244 cites W2070951834 @default.
• W2890773244 cites W2080033724 @default.
• W2890773244 cites W2091668320 @default.
• W2890773244 cites W2099828406 @default.
• W2890773244 cites W2110132657 @default.
• W2890773244 cites W2115738273 @default.
• W2890773244 cites W2124120186 @default.
• W2890773244 cites W2127960841 @default.
• W2890773244 cites W2143876041 @default.
• W2890773244 cites W2149429304 @default.
• W2890773244 cites W2155170531 @default.
• W2890773244 cites W2167459341 @default.
• W2890773244 cites W2173740168 @default.
• W2890773244 cites W2196410762 @default.
• W2890773244 cites W2217174511 @default.
• W2890773244 cites W2340241475 @default.
• W2890773244 cites W2341378930 @default.
• W2890773244 cites W2416547532 @default.
• W2890773244 cites W2494945167 @default.
• W2890773244 cites W2599076725 @default.
• W2890773244 cites W2609963590 @default.
• W2890773244 cites W2618993895 @default.
• W2890773244 cites W2765725161 @default.
• W2890773244 cites W2791931915 @default.
• W2890773244 cites W2800521692 @default.
• W2890773244 cites W2800666360 @default.
• W2890773244 cites W4213337569 @default.
• W2890773244 cites W4248429808 @default.
• W2890773244 doi "https://doi.org/10.3390/jcm7100320" @default.
• W2890773244 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6210595" @default.
• W2890773244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30282903" @default.
• W2890773244 hasPublicationYear "2018" @default.
• W2890773244 type Work @default.
• W2890773244 sameAs 2890773244 @default.
• W2890773244 citedByCount "5" @default.
• W2890773244 countsByYear W28907732442019 @default.
• W2890773244 countsByYear W28907732442020 @default.
• W2890773244 countsByYear W28907732442021 @default.
• W2890773244 countsByYear W28907732442022 @default.
• W2890773244 countsByYear W28907732442023 @default.
• W2890773244 crossrefType "journal-article" @default.
• W2890773244 hasAuthorship W2890773244A5009156847 @default.
• W2890773244 hasAuthorship W2890773244A5018068367 @default.
• W2890773244 hasAuthorship W2890773244A5023756839 @default.
• W2890773244 hasAuthorship W2890773244A5061507341 @default.
• W2890773244 hasBestOaLocation W28907732441 @default.
• W2890773244 hasConcept C108170787 @default.
• W2890773244 hasConcept C111472728 @default.
• W2890773244 hasConcept C138885662 @default.
• W2890773244 hasConcept C142724271 @default.
• W2890773244 hasConcept C159110408 @default.
• W2890773244 hasConcept C204787440 @default.
• W2890773244 hasConcept C2426938 @default.
• W2890773244 hasConcept C2778164427 @default.
• W2890773244 hasConcept C2778941218 @default.
• W2890773244 hasConcept C2779974597 @default.
• W2890773244 hasConcept C512399662 @default.
• W2890773244 hasConcept C71924100 @default.
• W2890773244 hasConceptScore W2890773244C108170787 @default.
• W2890773244 hasConceptScore W2890773244C111472728 @default.
• W2890773244 hasConceptScore W2890773244C138885662 @default.
• W2890773244 hasConceptScore W2890773244C142724271 @default.
• W2890773244 hasConceptScore W2890773244C159110408 @default.
• W2890773244 hasConceptScore W2890773244C204787440 @default.
• W2890773244 hasConceptScore W2890773244C2426938 @default.
• W2890773244 hasConceptScore W2890773244C2778164427 @default.
• W2890773244 hasConceptScore W2890773244C2778941218 @default.
• W2890773244 hasConceptScore W2890773244C2779974597 @default.
• W2890773244 hasConceptScore W2890773244C512399662 @default.
• W2890773244 hasConceptScore W2890773244C71924100 @default.
• W2890773244 hasIssue "10" @default.
• W2890773244 hasLocation W28907732441 @default.
• W2890773244 hasLocation W28907732442 @default.
• W2890773244 hasLocation W28907732443 @default.
• W2890773244 hasLocation W28907732444 @default.
• W2890773244 hasLocation W28907732445 @default.
• W2890773244 hasLocation W28907732446 @default.
• W2890773244 hasOpenAccess W2890773244 @default.

• next